<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The World Health Organization separates <z:hpo ids='HP_0011009'>acute</z:hpo> erythroid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (erythropoiesis in ≥50% of nucleated bone marrow cells; ≥20% myeloblasts of non-erythroid cells) from other entities with increased erythropoiesis - <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>-related changes (≥20% myeloblasts of <z:hpo ids='HP_0000001'>all</z:hpo> nucleated cells) or <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> - and subdivides <z:hpo ids='HP_0011009'>acute</z:hpo> erythroid <z:hpo ids='HP_0001909'>leukemia</z:hpo> into <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">erythroleukemia</z:e> and pure erythroid <z:hpo ids='HP_0001909'>leukemia</z:hpo> subtypes </plain></SENT>
<SENT sid="1" pm="."><plain>We aimed to investigate the biological/genetic justification for the different categories of <z:e sem="disease" ids="C0027022" disease_type="Neoplastic Process" abbrv="MPD">myeloid malignancies</z:e> with increased erythropoiesis (≥50% of bone marrow cells) </plain></SENT>
<SENT sid="2" pm="."><plain>DESIGN AND METHODS: We investigated 212 patients (aged 18.5-88.4 years) with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> or <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> characterized by 50% or more erythropoiesis: 108 had <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (77 with <z:hpo ids='HP_0011009'>acute</z:hpo> erythroid <z:hpo ids='HP_0001909'>leukemia</z:hpo>, corresponding to erythroid/myeloid <z:e sem="disease" ids="C0023440" disease_type="Neoplastic Process" abbrv="">erythroleukemia</z:e>, 7 with pure erythroid <z:hpo ids='HP_0001909'>leukemia</z:hpo>, 24 with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>-related changes) and 104 had <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Morphological and chromosome banding analyses were performed in <z:hpo ids='HP_0000001'>all</z:hpo> cases; subsets of cases were analyzed by polymerase chain reaction and immunophenotyping </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Unfavorable karyotypes were more frequent in patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> than in those with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (42.6% versus 13.5%; P&lt;0.0001), but their frequency did not differ significantly between patients with <z:hpo ids='HP_0011009'>acute</z:hpo> erythroid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (39.0%), pure erythroid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (57.1%), and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>-related changes (50.0%) </plain></SENT>
<SENT sid="5" pm="."><plain>The incidence of molecular mutations did not differ significantly between the different categories </plain></SENT>
<SENT sid="6" pm="."><plain>The 2-year overall survival rate was better for patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> than for those with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (P&lt;0.0001), without significant differences across the different <z:hpo ids='HP_0002488'>acute leukemia</z:hpo> subtypes </plain></SENT>
<SENT sid="7" pm="."><plain>The 2-year overall survival rate was worse in patients with unfavorable karyotypes than in those with intermediate risk karyotypes (P&lt;0.0001) </plain></SENT>
<SENT sid="8" pm="."><plain>In multivariate analysis, only <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> versus <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (P=0.021) and cytogenetic risk category (P=0.002) had statistically significant effects on overall survival </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSIONS: The separation of <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> with 50% or more erythropoietic cells has clinical relevance, but it might be worth discussing whether to replace the subclassifications of different subtypes of <z:hpo ids='HP_0011009'>acute</z:hpo> erythroid <z:hpo ids='HP_0001909'>leukemia</z:hpo> and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> with <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo>-related changes by the single entity, <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> with increased erythropoiesis ≥50% </plain></SENT>
</text></document>